Identified in prostate cancer as a posttranscriptional repressor of BRCA2 [149], PCAT1 also acts as competitive endogenous RNA (ceRNA) by sponging miR34-1 and abrogating its binding to MYC 3’UTR, thus increasing Myc protein levels [168]. Here, MYC is linked to Familial prostate cancer.